Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Department of Biomedical Sciences and Department of Thoracic and Cardiovascular Surgery, Korea University Guro Hospital, College of Medicine, Korea University, Seoul, 08308, South Korea.
Adv Healthc Mater. 2023 May;12(12):e2203134. doi: 10.1002/adhm.202203134. Epub 2023 Jan 25.
Two of the most pressing challenges facing bioimaging are nonspecific uptake of intravenously administered contrast agents and incomplete elimination of unbound targeted agents from the body. Designing a targeted contrast agent that shows fast clearance from background tissues and eventually the body after complete targeting is key to the success of image-guided interventions. Here, this work describes the development of renally clearable near-infrared contrast agents and their potential use for dual-channel image-guided tumor targeting. cRGD-ZW800-PEG (800 nm channel) and ZW700-PEG (700 nm channel) are able to visualize tumor margins and tumor vasculature simultaneously and respectively. These targeted agents show rapid elimination from the bloodstream, followed by renal clearance, which together significantly lower off-target background signals and potential toxicity. To demonstrate its applicability, this multispectral imaging is performed in various tumor-bearing animal models including lung cancer, pancreatic neuroendocrine tumors, breast, and ovarian cancer.
面临生物成像的两个最紧迫的挑战是静脉内给予的对比剂的非特异性摄取和未结合的靶向剂从体内不完全消除。设计一种靶向对比剂，在完全靶向后能够快速从背景组织中清除并最终从体内清除，这是图像引导干预成功的关键。在这里，这项工作描述了可清除肾脏的近红外对比剂的开发及其在双通道图像引导肿瘤靶向中的潜在用途。cRGD-ZW800-PEG（800nm 通道）和 ZW700-PEG（700nm 通道）能够分别同时可视化肿瘤边缘和肿瘤血管。这些靶向剂从血液中快速消除，随后经肾脏清除，这两者共同显著降低了非靶背景信号和潜在毒性。为了证明其适用性，在包括肺癌、胰腺神经内分泌肿瘤、乳腺和卵巢癌在内的各种肿瘤荷瘤动物模型中进行了这种多光谱成像。
